Biogen Is Faulted on Its Sale Process
121287
The investor Carl C. Icahn said he was trying to get three supporters elected to the board of the biotechnology firm Biogen Idec because of concerns over the sales process.
193614
The $73.5 billion global biotech business may soon have to grapple with a discovery that calls into question the scientific principles on which it was founded.
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
228014
Regulation and oversight has not kept pace with the development of new genetic tests and efforts to sell them directly to consumers.
60402
Biogen Idec Inc. BIIB.O on Monday  reported a quarterly profit on sales of its multiple sclerosis  and cancer drugs versus a year-ago loss, but said costs will  rise in 2005, trimming earnings growth.
723657
Could a jointly marketed drug lead to a joint company? Ireland&#39;s Sunday Tribune said yesterday that US pharmaceuticals company Biogen Idec (nasdaq: BIIB - news - people ) was looking to make an all-stock bid
142092
SAN FRANCISCO (CBS.MW) -- Shares of Elan Corp. and Biogen Idec rose in after-hours trading Tuesday after Tysabri, a drug used for the treatment of multiple sclerosis, was approved by the US Food and Drug Administration.
234249
Moving to strengthen its offerings to treat cancer, Biogen Idec Inc. of Cambridge yesterday signed a deal to license tumor-killing technology from ImmunoGen Inc.
260832
BOSTON  â The investor Carl C. Icahn said on Monday that he was trying to get three supporters elected to the board of the biotechnology firm Biogen Idec because of concerns over the sales process.
742369
One of the mantras of global industry  in recent years has been keeping inventories lean and mean, but  there are increasing signs this cost-cutting strategy is  creating strains and causing companies to miss out on sales.
307878
It&#39;s made by Biogen Idec and Elan. It was orginally called, Antegren until the US Food and Drug Administration requested a name change, to avoid confusion with other drugs.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
238313
A new study shows raises questions about the straying of plants altered through biotechnology and that could hurt the efforts of two companies to win approval for the first bioengineered grass.
374450
A genetic test marketed by Myriad Gentics is causing great concern among cancer and genetics experts.
336171
YESTERDAY Close $75.73 Change +$2.22 52-WEEK High $76.90 Low $58.71 Genzyme Corp. of Cambridge said profit jumped tenfold as sales increased for its medicines for rare genetic disorders, some of the world's costliest drugs. The company gained 3 percent in New York trading.
182389
After a quiet year for biotechnology, a sudden wave of mergers and buyouts has sparked interest in a business that relies on deal-making to put the stamp of success on new ideas.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.